Kazia Therapeutics


Market CapAU$153.8m

Last Close AU$1.17

Kazia Therapeutics’ lead asset is paxalisib, a PI3K inhibitor licensed from Genentech that can cross the BBB. It is entering a pivotal study for GBM and is being investigated for other brain cancers such as breast cancer brain metastases.

More Kazia Therapeutics content >

Investment summary

Kazia is developing the anti-cancer compound paxalisib (GDC-0084) for glioblastoma (GBM) multiforme. Paxalisib is a PI3K inhibitor, a well understood class with activity across a wide range of tumour types and multiple previously approved drugs. Paxalisib, unlike other drugs of this class, can cross the blood brain barrier (BBB), opening the potential to treat cancers of the brain. The pivotal GBM AGILE study is currently enrolling patients. The second product candidate is EVT801, a novel small molecule inhibitor VEGFR3. A Phase I trial of EVT801 in solid tumours recently started enrolling patients.

Y/E Jun
Revenue (A$m)
PBT (A$m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2020A 1.1 (10.8) (10.8) (14.19) N/A N/A
2021A 15.2 (4.4) (4.4) (3.62) N/A N/A
2022E 2.2 (16.3) (16.3) (11.53) N/A N/A
2023E 2.1 (15.2) (15.2) (10.25) N/A N/A
Industry outlook

GBM is the most common primary cancer of the brain with 11,500 new cases reported in the United States per year. There are very limited treatment options for GBM and there is a very low survival rate. Paxalisib is currently being developed for use in the adjuvant setting after initial resection and radiation treatment. EVT801 will target the multi billion angiogenesis cancer market.

Last updated on 18/01/2022
Content on Kazia Therapeutics
Kazia Therapeutics – introducing novel asset EVT-801
Healthcare | Edison TV | 25 October 2021
View more
Register to receive research on Kazia Therapeutics as it is published
Share price graph
Balance sheet
Forecast net cash (A$m) 11.6
Forecast gearing ratio (%) N/A
Price performance
Actual 8.4 (22.3) (11.1)
Relative* 6.8 (22.8) (20.3)
52-week high/low A$1.9/A$1.1
*% relative to local index
Key management
Iain Ross Chairman
James Garner CEO